AzTrials
AzTrials

Major Depressive DisorderPhase 2NCT00797966

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Phase 2 study testing OPC-34712 and ADT in people with Major Depressive Disorder, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 50 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Major Depressive Disorder
What is being tested?
OPC-34712 and ADT
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
850 participants
Where
50 sitesUnited States
Study dates
May 2009to Jul 2010
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria
  • The current depressive episode must be equal to or greater than 8 weeks in duration
  • Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than three adequate antidepressant treatments.

Who cannot join

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
  • Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
  • Subjects with a current Axis I (DSM-IV-TR) diagnosis of:
  • Delirium, dementia,amnestic or other cognitive disorder
  • Schizophrenia, schizoaffective disorder, or other psychotic disorder
  • Bipolar I or II disorder
  • Subjects with a clinically significant current Axis II (DSM-IV-TR)
  • diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.

Trial locations and contacts

50 sites in 1 country.

50 sites in 1 country

United States50 sites
  • Pacific Clinical Research Medical Group

    Arcadia, California, 91007

  • Community Clinical Research, Inc.

    Austin, Texas, 78754

  • FutureSearch Clinical Trials

    Austin, Texas, 78756

  • Pharmasite Research, Inc.

    Baltimore, Maryland, 21208

  • NorthCoast Clinical Trials, Inc

    Beachwood, Ohio, 44122

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007

  • Southwestern Research

    Beverly Hills, California, 90210

  • Florida Clinical Research Center, LLC

    Bradenton, Florida, 34208

  • Northbrooke Research Center

    Brown Deer, Wisconsin, 53223

  • Neuro-Behavioral Clinical Research, Inc

    Canton, Ohio, 44718

  • Carolinas HealthCare - Behavioral Heath Center

    Charlotte, North Carolina, 28211

  • Psychiatric Alliance of the Blue Ridge

    Charlottesville, Virginia, 22903

  • Uptown Research Institute

    Chicago, Illinois, 60640

  • Patient Priority Clinical Sites, LLC

    Cinncinnati, Ohio, 45242

  • USC School of Medicine- Department of Neuropsychiatry and Behavioral Science

    Columbia, South Carolina, 29203

  • CNS Clinical Research Group

    Coral Springs, Florida, 33065

  • Midwest Clinical Research Center

    Dayton, Ohio, 45408

  • Radiant Research Center

    Denver, Colorado, 80239

  • Synergy Escondido

    Escondido, California, 92025

  • Gulfcoast Clinical Research Center

    Fort Myers, Florida, 33912

  • Collaborative Neuroscience Network Inc.

    Garden Grove, California, 92845

  • NeuroScience, Inc.

    Herndon, Virginia, 20170

  • The Davis Clinic, PC

    Indianapolis, Indiana, 46260

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32216

  • Accurate Clinical Trials

    Kissimee, Florida, 34741

  • Suburban Research Associates

    Media, Pennsylvania, 19063

  • Clinical Neurosciences Solutions, Inc.

    Memphis, Tennessee, 38119

  • NorthStar Medical Research, LLC

    Middleburg Heights, Ohio, 44130

  • Dean Foundation

    Middleton, Wisconsin, 53562

  • Dominion Clinical Research

    Midlothian, Virginia, 23112

  • Bioscience Research

    Mount Kisco, New York, 10549

  • Synergy Clinical Research Center

    National City, California, 91950

  • Eastside Comprehensive Medical Center

    New York, New York, 10021

  • Medical & Behavioral Health Research, PC

    New York, New York, 10023

  • Midwest Center for Neurobehavioral Medicine

    Oakbrook Terrace, Illinois, 60181

  • Excell Research

    Oceanside, California, 92056

  • Clinical Neurosciences Solutions

    Orlando, Florida, 32806

  • Vince & Associates Clinical Research

    Overland Park, Kansas, 66212

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Summitt Research Network (Oregon)

    Portland, Oregon, 97210

  • Finger Lakes Clinical Research

    Rochester, New York, 14618

  • Radiant Research

    Salt Lake City, Utah, 84107

  • Mood Disorders Clinic

    Salt Lake City, Utah, 84132

  • Affiliated Research Institute

    San Diego, California, 92108

  • Summit Research Network (Seattle) LLC

    Seattle, Washington

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California, 91403

  • Carman Research

    Smyrna, Georgia, 30080

  • Stedman Clinical Trials

    Tampa, Florida, 33613

  • University of South Florida College of Medicine Psychiatry Center

    Tampa, Florida, 33613

  • Janus Center

    West Palm Beach, Florida, 33407

Other trials in United States

About this study

Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.

Read the detailed description

A comparison of the Fixed dose arm (OPC-31712, 0.15 mg) verses placebo was included as a general secondary efficacy variable and results for this dose group comparison are included under each of the Outcome Measures.

Being tested
OPC-34712, Placebo, ADT
Keywords
OPC-34712, Major Depressive Disorder, Adjunctive Treatment
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OPC-34712Drug

    Also called Generic Name: Brexpiprazole

    Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks

  • PlaceboDrug

    Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks

  • ADTDrug

    Also called Each individual will receive one of the following 6 ADTs:, Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine CR (Paxil CR)

    Tablets, 10 - 225 mgs, dose once daily, 14 weeks

Study groups in NCT00797966
Study groupRoleWhat they receive
1ExperimentalOPC-34712 + ADT
Receives: Drug: OPC-34712; Drug: ADT
2Placebo comparatorPlacebo + ADT
Receives: Drug: Placebo; Drug: ADT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

    The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.

    Measured: Week 8 to Week 14

Secondary outcomes (13)
  1. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.

    CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.

    Measured: Week 8 to Week 14

  2. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).

    The Q-LES-Q is a self-report measure to enable physicians to obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. The Overall-General Subscore will be defined by summing the scores on all 14 items and expressing it as the percent of the maximum possible score. When expressing the total score as a percentage, if items are left blank the range will be modified to reflect the number of items scored. Raw score is sum of non-missing ratings from items 1 to 14. Minimum score is number of non-missing items. Maximum score is 5*(minimum score). Range is maximum score minus minimum score. Total score is 100*(Raw score minus minimum score)/ Range, rounded to nearest integer.

    Measured: Week 8 to Week 14

  3. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).

    The Sheehan Disability Scale (SDS) is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

    Measured: Week 8 to Week 14

  4. Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

    The MADRS is utilized as the primary efficacy assessment of a patient's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.

    Measured: Week 8 to each of Week 9, 10, 11, 12 and 13.

  5. Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

    CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.

    Measured: Week 8 to each of Week 9, 10, 11, 12 and 13.

  6. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).

    The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 15 (Satisfaction with Medication) will yield a separate subscore.

    Measured: Week 8 to Week 14

  7. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).

    The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 16 (Overall Life Satisfaction) will yield a separate subscore.

    Measured: Week 8 to Week 14

  8. Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

    The IDS-SR is a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items are recorded. If the number of items was at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.

    Measured: Week 8 to each of Week 9, 10, 11, 12, 13 and 14

  9. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.

    The HAM-D17 is utilized as a secondary assessment of a participant's level of depression. The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The possible total scores are from 0 to 52.

    Measured: Week 8 to Week 14

  10. Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.

    CGI-I items are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI-I was assessed at each visit in Phase B, and improvement is judged with respect to the participant's condition at baseline. CGI-I was also assessed at each visit in Phase B, but in that phase improvement is judged with respect to the partcipant's condition at the end of Phase A.

    Measured: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

  11. Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).

    A MADRS response was defined as >/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).

    Measured: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

  12. Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).

    A MADRS remission was defined as MADRS Total Score </= 10 and >/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).

    Measured: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

  13. Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).

    CGI-I response is defined as CGI-I of 1 [very much improved] or 2 [much improved].

    Measured: Week 9, 10, 11, 12, 13 and 14.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2008 (estimated)
  2. Study startMay 2009
  3. Primary completionJun 2010
  4. Study completionJul 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
850 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00797966
Sponsor's protocol ID
331-08-211
Status last verified
Feb 2016
First submitted
24 Nov 2008
Last updated
29 Feb 2016
Data monitoring committee
Yes

Publications

  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095.

    PubMed 30508090

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing OPC-34712 and ADT in people with Major Depressive Disorder, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 50 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 50 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Dec 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score. (time frame: Week 8 to Week 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00797966, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in